Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Preferred Pharmaceuticals, Inc.

Preferred Pharmaceuticals, Inc. Recalls

All product recalls associated with Preferred Pharmaceuticals, Inc..

Get alerts for this brand

Recall Summary

Total Recalls

Past Year

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 41–54 of 54 recalls

Nature-Throid 1.5 Grain (Preferred Pharmaceuticals) – CGMP Deviation (2020)

CGMP Deviations

Class IIModerate

FDASep 2, 2020CA, GA, IN• Preferred Pharmaceuticals, Inc.

Nature-Throid 1 Grain (Preferred Pharmaceuticals) – CGMP Deviation (2020)

CGMP Deviations

Class IIModerate

FDASep 2, 2020CA, GA, IN• Preferred Pharmaceuticals, Inc.

Lidothol Patch (Preferred Pharmaceuticals) – Record Misplacement (2020)

CGMP Deviations: Contract Manufacturing Organization (CMO) misplaced/lost batch records and test results for the recalled batch.

Class IIModerate

1 23

Page 3 of 3Next

FDA

Jul 1, 2020

Nationwide

• Preferred Pharmaceuticals, Inc.

Metformin Extended Release (Preferred Pharmaceuticals) – NDMA Impurity (2020)

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Class IIModerate

FDAJun 17, 2020FL, IN• Preferred Pharmaceuticals, Inc.

Ranitidine Tablets (Preferred Pharmaceuticals) – NDMA Contamination (2020)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAJan 7, 2020AL, AZ, CA +4 more• Preferred Pharmaceuticals, Inc

Ranitidine Tablets (Preferred Pharmaceuticals) – NDMA Contamination (2020)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDAJan 7, 2020AL, AZ, CA +4 more• Preferred Pharmaceuticals, Inc

Ranitidine Tablets (Preferred Pharma) – NDMA Impurity (2019)

CGMP Deviations: Presence of NDMA impurity detected in product.

Class IIModerate

FDADec 2, 2019CA, FL• Preferred Pharmaceuticals, Inc

Ibuprofen Oral Suspension (Preferred) – Foreign Particles (2019)

Presence of foreign substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

Class IIModerate

FDANov 21, 2019CA, FL, IL• Preferred Pharmaceuticals, Inc

Fexofenadine Tablets (Preferred Pharmaceuticals) – Impurity Failure (2019)

Failed Impurities/Degradation Specifications

Class IIModerate

FDAAug 29, 2019FL, IN• Preferred Pharmaceuticals, Inc

Neomycin-Polymyxin-Dexamethasone (Preferred Pharmaceuticals) – Quality Control (2019)

CGMPs Deviations: Insufficient Quality Assurance controls over critical systems in the manufacturing facility.

Class IIModerate

FDAJul 18, 2019CA, FL• Preferred Pharmaceuticals, Inc

Robafen DM (Preferred Pharmaceuticals) – Contamination Risk (2019)

CGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Class IIModerate

FDAJun 10, 2019CA, FL• Preferred Pharmaceuticals, Inc

Losartan Potassium Tablets (Preferred Pharmaceuticals) – NMBA Impurity (2019)

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer

Class IIModerate

FDAApr 30, 2019CA, GA, IN +1 more• Preferred Pharmaceuticals, Inc

Losartan Potassium Tablets (Preferred) – CGMP Impurity (2019)

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) was identified.

Class IIModerate

FDAMar 6, 2019CA, GA, IN• Preferred Pharmaceuticals, Inc

Valsartan Tablets 320mg (Preferred Pharmaceuticals) – carcinogen impurity (2018)

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Class IIModerate

FDAAug 15, 2018AL, IN• Preferred Pharmaceuticals, Inc